Last reviewed · How we verify
Vonorasan Fumarate
At a glance
| Generic name | Vonorasan Fumarate |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding (PHASE2)
- Zuojin Wan Combined With Woonosan Fumarate for the Treatment of GRD Combined With Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonorasan Fumarate CI brief — competitive landscape report
- Vonorasan Fumarate updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI